Expert Interview
Discussing Arrowhead's plozasiran for managing persistent chylomicronemia and pancreatitis risk with FCS after receiving FDA breakthrough therapy designation
Ticker(s): ARWR, IONSInstitution: Western University
- Distinguished Professor of Medicine and Biochemistry at Western University in London, Ontario, Canada.
- Manages >2500 patients in his lipid clinic, 25 with FCS.
- His laboratory discovered the causal genes and first pathogenic variants for >20 human diseases, and also developed the world’s first targeted next-generation sequencing panel for dyslipidemias.
- He was among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes, has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabete, and has published >900 papers.
Roughly how many patients with FCS do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for plozasiran?
Added By: c_adminCan you provide an introduction to your clinical practice, research interests, and how patients are typically diagnosed with FCS, considering its rarity?
Regarding the prevalence of persistent SHTG (or whatever you choose to call it), how does it compare to FCS, and is there any data suggesting patients with persistent chylomicronemia outside of FCS wouldn't experience a similar reduction in acute pancreatitis risk?
How do you compare and contrast the current treatment options, particularly plozasiran and olezarsen, and do you have a preference based on efficacy, safety, or patient outcomes?
Are there any significant concerns about the platelet issues with olezarsen, and what challenges have you encountered with patient access or payer approval, particularly for high-cost drugs like evinacumab?
Added By: slingshot_insightsHow aware are clinicians and patients of these new treatments, and is there anything I haven't asked about FCS or related treatments that you think is important to discuss?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
